UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $761.22 Million Position in Zoetis Inc. (NYSE:ZTS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 5.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,896,106 shares of the company’s stock after buying an additional 194,542 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Zoetis were worth $761,221,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Quarry LP grew its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the period. Finally, Fortitude Family Office LLC grew its stake in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.6 %

ZTS opened at $176.74 on Thursday. The company has a fifty day moving average price of $184.51 and a 200-day moving average price of $180.81. The firm has a market capitalization of $79.74 billion, a P/E ratio of 33.22, a price-to-earnings-growth ratio of 2.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the firm posted $1.36 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ZTS shares. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.